The patent application WO2003077914A1, titled "Pyrrole and Pyrazole Compounds as MEK Inhibitors," describes a class of compounds, including binimetinib (also known as MEK162), that act as inhibitors of MEK1 and MEK2 kinases [1]. These kinases are involved in the MAPK signaling pathway, which plays a role in cell proliferation and survival. Binimetinib has been investigated for its potential in treating various cancers, particularly those with activating mutations in the BRAF or RAS genes [1, 2].
What is the mechanism of action for binimetinib?
Binimetinib selectively inhibits MEK1 and MEK2, which are upstream kinases in the RAS-RAF-MEK-ERK signaling pathway [1]. By blocking MEK, binimetinib prevents the phosphorylation and activation of ERK1 and ERK2, thereby inhibiting downstream signaling that promotes tumor cell growth and survival [1, 2]. This pathway is frequently dysregulated in cancers like melanoma, non-small cell lung cancer, and thyroid cancer [2].
When does the patent protection for binimetinib expire?
The patent application WO2003077914A1 represents an early stage of intellectual property protection. Drug patents, including those for binimetinib, can have complex expiration timelines due to factors such as filing dates, patent term extensions, and any subsequent patent filings. Specific expiration dates can be tracked through resources like DrugPatentWatch.com [3].
Who developed binimetinib and what companies are involved?
Binimetinib was developed by Array BioPharma, which was later acquired by Pfizer Inc. [2, 4]. The commercialization and further development of binimetinib, often in combination with other targeted therapies, have been carried out by Pfizer [2, 4].
What are the clinical indications for binimetinib?
Binimetinib, often in combination with encorafenib, is approved for the treatment of certain types of melanoma with BRAF mutations [2]. It has also been studied in other solid tumors with activating mutations in the MAPK pathway, such as non-small cell lung cancer and colorectal cancer, as well as in patients with NRAS-mutant melanoma [2, 5]. Clinical trials continue to explore its efficacy in various oncological settings [5].
What are the key safety concerns or side effects associated with binimetinib?
Common side effects reported in clinical trials for binimetinib include gastrointestinal issues such as diarrhea, nausea, and vomiting, as well as skin reactions, fatigue, and elevated liver enzymes [2, 5]. More serious adverse events can include cardiac issues, ocular toxicity (retinal vein occlusion), and vision impairment [2, 5]. Patient monitoring is crucial during treatment.
How does binimetinib compare to other MEK inhibitors?
Binimetinib is one of several MEK inhibitors available, alongside drugs like trametinib, cobimetinib, and selumetinib [6]. These inhibitors share a similar mechanism of action but differ in their pharmacokinetic profiles, selectivity, and approved indications [6]. The choice of MEK inhibitor often depends on the specific cancer type, genetic mutations, and treatment context, as well as combination therapy strategies [2, 6].
What is the potential for generic or biosimilar competition for binimetinib?
The availability of generic or biosimilar versions of binimetinib depends on the expiry of its relevant patents and any regulatory exclusivities [3]. Once patents expire, and regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions of the drug. For biologics, biosimilars are the equivalent, but binimetinib is a small molecule drug, so generic competition is the relevant pathway.
Where can I find more information on binimetinib patents and litigation?
Detailed information regarding patent filings, expirations, and any related litigation for binimetinib can be found through specialized intellectual property databases and patent tracking services, such as DrugPatentWatch.com [3]. These resources provide insights into the patent landscape surrounding pharmaceutical products.
---
Sources:
[1] WO2003077914A1, Pyrrole and Pyrazole Compounds as MEK Inhibitors.
[2] ClinicalTrials.gov. (n.d.). Binimetinib. Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=binimetinib&cntry=&state=&city=&dist=
[3] DrugPatentWatch.com. (n.d.). Binimetinib. Retrieved from https://drugpatentwatch.com/
[4] Pfizer Inc. (n.d.). Retrieved from https://www.pfizer.com/
[5] Ribas, A., et al. (2017). Quality of Life and Safety of Encorafenib Plus Binimetinib Versus Vemurafenib in Patients With BRAF V600–Mutant Melanoma. Journal of Clinical Oncology, 35(34), 3805-3812.
[6] Saussez, S., et al. (2017). The MEK Inhibitors in Oncology. Future Oncology, 13(22), 1953-1973.